BioMarin Pharmaceutical Inc
BMRN
NASDAQ
Biotechnology
$67.36
USD
-1.17 (-1.71%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $13.35B
Volume 1.4M
Revenue
$3.41B
TTM
+11.2%
YoY
Gross Margin
76%
TTM
-4.3%
YoY
Net Income
$72.97M
TTM
-88.9%
YoY
Operating Cash Flow
$857.09M
TTM
+11.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 825.4 | 776.1 | 874.6 | 766.2 | 989.7 |
YoY Growth | +15.9% | +4.1% | +17.0% | +2.8% | +19.9% |
Cost of Revenue | 150.1 | 140.1 | 275.7 | 195.0 | 202.8 |
Gross Profit | 675.3 | 636.0 | 598.9 | 571.2 | 786.9 |
Selling, General & Administrative | 232.3 | 268.4 | 446.2 | 258.3 | 395.5 |
Other Operating Expenses | -4.8 | 0.0 | 0.0 | 0.0 | -3.3 |
Total Operating Expenses | 393.6 | 682.7 | 643.5 | 441.6 | 672.7 |
Operating Income | 281.7 | -46.7 | -44.6 | 129.6 | 114.2 |
EBITDA | 300.3 | -28.2 | -24.2 | 146.1 | 211.8 |
Other Income / Expense | 0.0 | 5.1 | 1.0 | 4.0 | 0.0 |
Total Other Income / Expense | 16.1 | 20.4 | 17.5 | 11.6 | -52.8 |
Income Before Income Taxes | 297.9 | -26.3 | -27.2 | 141.2 | 61.4 |
Income Taxes | 57.3 | 4.4 | 19.4 | 35.7 | 16.6 |
Net Income | 240.5 | -30.7 | -46.6 | 105.5 | 44.8 |
Consolidated Net Income / Loss | 240.5 | -30.7 | -46.6 | 105.5 | 44.8 |
Net Income Attributable to Common Shareholders | 240.5 | -30.7 | -46.6 | 105.5 | 44.8 |
Basic EPS | $1.25 | -$0.16 | -$0.24 | $0.55 | $0.23 |
Diluted EPS | $1.23 | -$0.16 | -$0.23 | $0.54 | $0.23 |
Basic Shares Outstanding | 191.9M | 192.0M | 192.2M | 192.5M | 193.4M |
Diluted Shares Outstanding | 197.1M | 192.0M | 204.0M | 197.7M | 194.5M |